Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Resverlogix has completed dosing of its Phase Ia safety, tolerability and pharmacokinetics study for the company's lead dyslipidemia drug candidate, RVX-208.
Subscribe to our email newsletter
The primary objectives of the Phase Ia trial were to examine the safety, tolerability and pharmacokinetics of RVX-208. This study successfully met those objectives. In addition to the completed Phase Ia human clinical trial, RVX-208 has been the subject of 126 preclinical studies to date, comprising safety, toxicity, pharmacokinetics and pharmacology studies. The company has also selected the dosages to be used in the 28-day Phase Ib/IIa study.
Donald McCaffrey, president and CEO of Resverlogix, said: “Initial results from the emerging data are very good. With these successful results in hand we are now planning for our Phase Ib/IIa trial which, pending discussions and approval from the FDA, we expect to start later this year.”